Given the present result, an anti-MCP1 strategy or a better understanding of the mechanism of immunotherapeutic agents may have potential therapeutic value to reduce the detrimental interrelationship between FGF23, dyslipidemia, and inflammation based on CV pathophysiological mechanisms in CKD. Here, CCL2 is linked to chronic kidney disease.